Lillian Skidmore

410 total citations
11 papers, 192 citations indexed

About

Lillian Skidmore is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lillian Skidmore has authored 11 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lillian Skidmore's work include Radiopharmaceutical Chemistry and Applications (6 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Lillian Skidmore is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Lillian Skidmore collaborates with scholars based in Italy and United States. Lillian Skidmore's co-authors include Nick Knudsen, Sandra L. Biroc, Yi Gu, Sulan Yao, Feng Tian, Robin Marsden, Wayne Yu, Sukumar Sakamuri, Snezana Milutinovic and Robin Humphreys and has published in prestigious journals such as PLoS ONE, Cancer Research and Annals of Oncology.

In The Last Decade

Lillian Skidmore

11 papers receiving 185 citations

Peers

Countries citing papers authored by Lillian Skidmore

Since Specialization

Citations

This map shows the geographic impact of Lillian Skidmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lillian Skidmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lillian Skidmore more than expected).

Fields of papers citing papers by Lillian Skidmore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lillian Skidmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lillian Skidmore. The network helps show where Lillian Skidmore may publish in the future.

Co-authorship network of co-authors of Lillian Skidmore

This figure shows the co-authorship network connecting the top 25 collaborators of Lillian Skidmore. A scholar is included among the top collaborators of Lillian Skidmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lillian Skidmore. Lillian Skidmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Title	Journal	Authors	Indexed citations
1	Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer	Molecular Cancer Therapeutics	Lillian Skidmore, David Mills et al.	6
2	Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle	Frontiers in Microbiology	Paul A. Azzinaro, Peter C. Canning et al.	1
3	Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types	Cancer Research	David Mills, Erica M. Wood et al.	1
4	41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models	Annals of Oncology	Xiaofeng Zhang, N. Knudsen et al.	2
5	1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)	Annals of Oncology	Scott T. Tagawa, Jianzhong Shen et al.	2
6	Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development	PLoS ONE	Wayne Yu, Mysore P. Ramprasad et al.	4
7	Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer	Cancer Research	Lillian Skidmore, David Mills et al.	3
8	Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate	Cancer Research	Mingchao Kang, Andy Beck et al.	3
9	ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers	Molecular Cancer Therapeutics	Lillian Skidmore, Sukumar Sakamuri et al.	121
10	Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment	Molecular Cancer Therapeutics	Jingjing Zhu, Lillian Skidmore et al.	22
11	Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers	Cancer Research	Robin Humphreys, Sandra L. Biroc et al.	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact